{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:40:16Z","timestamp":1793108416369,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.colsurfb.2022.112351","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T02:30:14Z","timestamp":1642645814000},"page":"112351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A topical fluorometholone nanoformulation fabricated under aqueous condition for the treatment of dry eye"],"prefix":"10.1016","volume":"212","author":[{"given":"Tian-zuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-nan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-hui","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtos.2018.11.003","article-title":"The impact of dry eye disease treatment on patient satisfaction and quality of life: a review","volume":"17","author":"Gomes","year":"2019","journal-title":"Ocul. Surf."},{"issue":"18","key":"10.1016\/j.colsurfb.2022.112351_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"n\u22123 Fatty acid supplementation for the treatment of dry eye disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2022.112351_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2021.100429","article-title":"Anchoring polyethylene glycol to the ocular surface by phenylboronic acid functionalization: Implications for fabrication of long-acting artificial tears","volume":"42","author":"Gong","year":"2021","journal-title":"Colloid Interface Sci. Commun."},{"key":"10.1016\/j.colsurfb.2022.112351_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.actbio.2017.03.043","article-title":"Targeted delivery of hyaluronic acid to the ocular surface by a polymer-peptide conjugate system for dry eye disease","volume":"55","author":"Lee","year":"2017","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.colsurfb.2022.112351_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09273948.2017.1341988","article-title":"The use of topical corticosteroids for treatment of dry eye syndrome","volume":"27","author":"Cutolo","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.colsurfb.2022.112351_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2019.10.039","article-title":"A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease","volume":"315","author":"Yu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2022.112351_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/ICL.0000000000000666","article-title":"Current and future pharmacological therapies for the management of dry eye","volume":"46","author":"Gupta","year":"2020","journal-title":"Eye & Contact Lens"},{"key":"10.1016\/j.colsurfb.2022.112351_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.colsurfb.2018.11.065","article-title":"In-situ forming gels containing fluorometholone-loaded polymeric nanoparticles for ocular inflammatory conditions","volume":"175","author":"Gonzalez-Pizarro","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijpharm.2018.05.050","article-title":"Development of fluorometholone-loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye","volume":"547","author":"Gonzalez-Pizarro","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2022.112351_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120067","article-title":"The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes","volume":"592","author":"Baba","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.colsurfb.2022.112351_bib11","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1111\/aos.14113","article-title":"Fluorometholone modulates gene expression of ocular surface mucins","volume":"97","author":"Taniguchi","year":"2019","journal-title":"Acta Ophthalmol."},{"issue":"4","key":"10.1016\/j.colsurfb.2022.112351_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040208","article-title":"Development and evaluation of a water soluble fluorometholone eye drop formulation employing polymeric micelle","volume":"10","author":"Noh","year":"2018","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/13102818.2019.1656107","article-title":"Combined use of 0.1% fluorometholone and meibomian gland expression improves symptoms of moderate and severe dry eye disease, even in patients with systemic immune disease","volume":"33","author":"Guo","year":"2019","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"2","key":"10.1016\/j.colsurfb.2022.112351_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jop.2016.0151","article-title":"Dose uniformity of topical corticosteroids: a simulated trial of fluorometholone acetate 0.1% and loteprednol etabonate gel 0.5%","volume":"33","author":"Stevens","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.colsurfb.2022.112351_bib15","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0039-6257(99)00111-3","article-title":"Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies","volume":"44","author":"Silver","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2022.112351_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/aos.14861","article-title":"Aqueous eye drops containing drug\/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment","volume":"100","author":"Loftsson","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.colsurfb.2022.112351_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2020.06.016","article-title":"Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system","volume":"154","author":"Senjoti","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2022.112351_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/aos.14639","article-title":"Angiotensin receptor blockers in cyclodextrin nanoparticle eye drops: ocular pharmacokinetics and pharmacologic effect on intraocular pressure","volume":"99","author":"Lorenzo-Soler","year":"2021","journal-title":"Acta Ophthalmol."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2015.07.040","article-title":"Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations","volume":"493","author":"J\u00f3hannsd\u00f3ttir","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.colsurfb.2022.112351_bib20","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.drudis.2019.05.006","article-title":"Therapeutic implications of nanomedicine for ocular drug delivery","volume":"24","author":"Meng","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2022.112351_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110726","article-title":"Encapsulating curcumin in ethylene diamine-\u03b2-cyclodextrin nanoparticle improves topical cornea delivery","volume":"186","author":"Liu","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2022.112351_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116114","article-title":"Biocompatible cellulose-based supramolecular nanoparticles driven by host\u2013guest interactions for drug delivery","volume":"237","author":"Yang","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.colsurfb.2022.112351_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.carbpol.2019.04.056","article-title":"Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages","volume":"218","author":"Yunus Basha","year":"2019","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010005","article-title":"Nanoparticles based on quaternary ammonium chitosan-methyl-\u03b2-cyclodextrin conjugate for the neuropeptide dalargin delivery to the central nervous system: an in vitro study","volume":"13","author":"Migone","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.colsurfb.2022.112351_bib25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1021\/ar500055s","article-title":"Cyclodextrin-based host\u2013guest supramolecular nanoparticles for delivery: from design to applications","volume":"47","author":"Hu","year":"2014","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.colsurfb.2022.112351_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ma12020229","article-title":"Nepafenac-loaded cyclodextrin\/polymer nanoaggregates: a new approach to eye drop formulation","volume":"12","author":"Lorenzo-Veiga","year":"2019","journal-title":"Materials"},{"key":"10.1016\/j.colsurfb.2022.112351_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejps.2016.03.012","article-title":"Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration","volume":"92","author":"Rodr\u00edguez Villanueva","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.colsurfb.2022.112351_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"14","key":"10.1016\/j.colsurfb.2022.112351_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7194","article-title":"Smart contact lens and transparent heat patch for remote monitoring and therapy of chronic ocular surface inflammation using mobiles","volume":"7","author":"Jang","year":"2021","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.colsurfb.2022.112351_bib30","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.xphs.2016.01.019","article-title":"Self-assembly of cyclodextrins and their complexes in aqueous solutions","volume":"105","author":"Ryzhakov","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2022.112351_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ijbiomac.2020.04.115","article-title":"Trimethyl chitosan nanoparticles for ocular baicalein delivery: preparation, optimization, in vitro evaluation, in vivo pharmacokinetic study and molecular dynamics simulation","volume":"156","author":"Li","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.colsurfb.2022.112351_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1021\/cg050500+","article-title":"Crystalline cyclodextrin inclusion compounds formed with aromatic guests: guest-dependent stoichiometries and hydration-sensitive crystal structures","volume":"6","author":"Uyar","year":"2006","journal-title":"Cryst. Growth Des."},{"issue":"4","key":"10.1016\/j.colsurfb.2022.112351_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10856-018-6048-2","article-title":"A water-soluble, mucoadhesive quaternary ammonium chitosan-methyl-\u03b2-cyclodextrin conjugate forming inclusion complexes with dexamethasone","volume":"29","author":"Piras","year":"2018","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.colsurfb.2022.112351_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.carbpol.2016.12.009","article-title":"Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles","volume":"159","author":"Kang","year":"2017","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.colsurfb.2022.112351_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jps.2600750316","article-title":"Effect of particle dissolution rate on ocular drug bioavailability","volume":"75","author":"Hui","year":"1986","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.colsurfb.2022.112351_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0b013e31820687dd","article-title":"Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in Patients with dry eye syndrome","volume":"30","author":"Yoon","year":"2011","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.colsurfb.2022.112351_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0b013e3181930c03","article-title":"Staining patterns in dry eye syndrome: rose bengal versus lissamine green","volume":"28","author":"Machado","year":"2009","journal-title":"Cornea"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776522000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776522000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:06:31Z","timestamp":1760526391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776522000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":37,"alternative-id":["S0927776522000340"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112351","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A topical fluorometholone nanoformulation fabricated under aqueous condition for the treatment of dry eye","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112351"}}